Skip to main content
Premium Trial:

Request an Annual Quote

Sysmex Inostics AML-MRD-SEQ

Sysmex Inostics has launched a new CLIA-validated liquid biopsy test for the detection of minimal residual disease in Acute Myeloid Leukemia. The test, AML-MRD-SEQ, is initially being offered for clinical trial use but will eventually be available to physicians and patients. According to Sysmex, AML-MRD-SEQ is a more expansive panel than previous MRD assays, covering 68 regions across 20 genes, including established MRD markers such as NPM1.